AR079941A2 - Organismos clostridium atenuados recombinados y vacuna - Google Patents
Organismos clostridium atenuados recombinados y vacunaInfo
- Publication number
- AR079941A2 AR079941A2 ARP110100176A ARP110100176A AR079941A2 AR 079941 A2 AR079941 A2 AR 079941A2 AR P110100176 A ARP110100176 A AR P110100176A AR P110100176 A ARP110100176 A AR P110100176A AR 079941 A2 AR079941 A2 AR 079941A2
- Authority
- AR
- Argentina
- Prior art keywords
- organisms
- attentioned
- recombined
- vaccine
- attenuated
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000193403 Clostridium Species 0.000 title 1
- 101710092462 Alpha-hemolysin Proteins 0.000 abstract 3
- 101710197219 Alpha-toxin Proteins 0.000 abstract 3
- 101710124951 Phospholipase C Proteins 0.000 abstract 3
- 239000002776 alpha toxin Substances 0.000 abstract 3
- 230000002238 attenuated effect Effects 0.000 abstract 3
- 241000193468 Clostridium perfringens Species 0.000 abstract 2
- 101100069896 Caenorhabditis elegans his-68 gene Proteins 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fodder In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Feed For Specific Animals (AREA)
Abstract
Organismos Clostridium perfringens atenuados, que expresan una toxina alfa sustancialmente no toxica. La toxina alfa expresada es una muteína de delecion a la que, en relacion con la toxina alfa de la toxina alfa madura de la cepa 13 de Clostridium perfringens, le faltan por lo menos 9 residuos de aminoácidos consecutivos, que incluyen His68. La presente acta revela además organismos atenuados que codifican las muteínas, y también, el uso de dichos organismos atenuados como vacunas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79255306P | 2006-04-17 | 2006-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079941A2 true AR079941A2 (es) | 2012-02-29 |
Family
ID=38625523
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101608A AR060471A1 (es) | 2006-04-17 | 2007-04-16 | Organismos clostridium recombinantes atenuados y vacuna |
| ARP110100176A AR079941A2 (es) | 2006-04-17 | 2011-01-19 | Organismos clostridium atenuados recombinados y vacuna |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101608A AR060471A1 (es) | 2006-04-17 | 2007-04-16 | Organismos clostridium recombinantes atenuados y vacuna |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US7732187B2 (es) |
| EP (2) | EP2368571A1 (es) |
| JP (2) | JP5551933B2 (es) |
| KR (1) | KR20080110908A (es) |
| CN (1) | CN101489584B (es) |
| AR (2) | AR060471A1 (es) |
| AU (1) | AU2007240949B2 (es) |
| BR (1) | BRPI0711572A2 (es) |
| CA (1) | CA2649426C (es) |
| CO (1) | CO6140037A2 (es) |
| EC (1) | ECSP088827A (es) |
| ES (1) | ES2401810T3 (es) |
| IL (1) | IL194714A (es) |
| MX (1) | MX2008013451A (es) |
| NO (1) | NO20084810L (es) |
| NZ (1) | NZ571970A (es) |
| PE (1) | PE20080167A1 (es) |
| PL (1) | PL2007420T3 (es) |
| RU (2) | RU2593945C2 (es) |
| TW (1) | TWI338045B (es) |
| UA (2) | UA109105C2 (es) |
| WO (1) | WO2007123850A2 (es) |
| ZA (1) | ZA200808872B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070077256A1 (en) | 1999-11-19 | 2007-04-05 | Los Angeles Biomedical Research Institute | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| US20060083750A1 (en) * | 1999-11-19 | 2006-04-20 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis |
| WO2009134891A2 (en) * | 2008-04-29 | 2009-11-05 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
| EP2613802A4 (en) * | 2010-09-10 | 2014-03-26 | Viropharma Inc | ENVIRONMENTAL CLOSTRIDAL BACTERIOTHERAPY AND ASSOCIATED FORMULATIONS AND METHODS OF MAKING AND USING SAME |
| EP2734229B1 (en) | 2011-07-22 | 2019-01-02 | Novadigm Therapeutics, Inc. | Methods and copositions for vaccinating against staphylococcus aureus |
| SG10201610123UA (en) * | 2012-03-02 | 2017-01-27 | Regeneron Pharma | Human antibodies to clostridium difficile toxins |
| EP2911688B1 (en) | 2012-10-26 | 2019-10-16 | Intervet International B.V. | Cross-protecting salmonella vaccines |
| CA2906771A1 (en) | 2013-03-15 | 2014-09-18 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Compositions and methods for treating fungal and bacterial pathogens |
| WO2017155949A1 (en) | 2016-03-09 | 2017-09-14 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Methods and kits for use in preventing and treating vulvovaginal candidiasis |
| CN109602898B (zh) * | 2018-12-28 | 2022-02-22 | 江苏省农业科学院 | 一种产气荚膜梭菌α毒素基因工程疫苗及其制备方法 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| GB202019767D0 (en) | 2020-12-15 | 2021-01-27 | Chain Biotechnology Ltd | Compostitions and methods |
| CN114621963A (zh) * | 2022-03-11 | 2022-06-14 | 牧原食品股份有限公司 | 一种猪魏氏梭菌a型的亚单位疫苗及其制备 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1483042A (en) * | 1974-07-29 | 1977-08-17 | Lapointe J | Anti-tumour product of bacterial origin |
| SU627612A1 (ru) | 1977-09-30 | 1980-02-05 | Zemlyakova V P | Препарат земл ковой в.п. против клюстридиозов животных и птиц |
| GB9115332D0 (en) * | 1991-07-16 | 1991-08-28 | Connaught Lab | Manipulation of gene copy number in bordetella |
| MX9302964A (es) * | 1992-05-20 | 1995-01-31 | Secr Defence | Vacunas de clostridium perfringens. |
| GB9605222D0 (en) | 1996-03-12 | 1996-05-15 | Secr Defence | Clostridium perfringens epsilon toxin vaccines |
| DE69836520T2 (de) * | 1997-06-20 | 2007-06-06 | Intervet International B.V. | Clostridium perfringens Impfstoff |
| RU2129441C1 (ru) * | 1997-12-10 | 1999-04-27 | Пирожков Михаил Константинович | Вакцина, ассоциированная против анаэробной энтеротоксемии и эшерихиоза поросят |
| US6399074B1 (en) * | 1998-07-24 | 2002-06-04 | Megan Health, Inc. | Live attenuated salmonella vaccines to control avian pathogens |
| AUPQ899700A0 (en) * | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| EP1569687B1 (en) * | 2002-12-09 | 2010-10-06 | University Of Georgia Research Foundation, Inc. | Coccidial vaccine and methods of making and using same |
| WO2005046721A2 (en) * | 2003-11-10 | 2005-05-26 | Uab Research Foundation | Compositions for reducing bacterial carriage and cns invasion and methods of using same |
| MY149604A (en) * | 2005-04-18 | 2013-09-13 | Schering Plough Ltd | C.perfringens alpha toxoid vaccine |
-
2007
- 2007-04-12 RU RU2011147308/10A patent/RU2593945C2/ru active
- 2007-04-12 EP EP11157448A patent/EP2368571A1/en not_active Withdrawn
- 2007-04-12 KR KR1020087027923A patent/KR20080110908A/ko not_active Ceased
- 2007-04-12 MX MX2008013451A patent/MX2008013451A/es active IP Right Grant
- 2007-04-12 AU AU2007240949A patent/AU2007240949B2/en not_active Ceased
- 2007-04-12 PL PL07755417T patent/PL2007420T3/pl unknown
- 2007-04-12 EP EP07755417A patent/EP2007420B1/en active Active
- 2007-04-12 UA UAA201106572A patent/UA109105C2/ru unknown
- 2007-04-12 CA CA2649426A patent/CA2649426C/en not_active Expired - Fee Related
- 2007-04-12 JP JP2009506518A patent/JP5551933B2/ja not_active Expired - Fee Related
- 2007-04-12 RU RU2008144913/10A patent/RU2445364C2/ru active
- 2007-04-12 WO PCT/US2007/009135 patent/WO2007123850A2/en not_active Ceased
- 2007-04-12 NZ NZ571970A patent/NZ571970A/en not_active IP Right Cessation
- 2007-04-12 CN CN2007800225963A patent/CN101489584B/zh not_active Expired - Fee Related
- 2007-04-12 ES ES07755417T patent/ES2401810T3/es active Active
- 2007-04-12 US US11/734,454 patent/US7732187B2/en active Active
- 2007-04-12 BR BRPI0711572-5A patent/BRPI0711572A2/pt not_active IP Right Cessation
- 2007-04-16 AR ARP070101608A patent/AR060471A1/es active IP Right Grant
- 2007-04-16 PE PE2007000464A patent/PE20080167A1/es not_active Application Discontinuation
- 2007-04-17 TW TW096113489A patent/TWI338045B/zh not_active IP Right Cessation
- 2007-12-04 UA UAA200813301A patent/UA95951C2/ru unknown
-
2008
- 2008-10-12 IL IL194714A patent/IL194714A/en not_active IP Right Cessation
- 2008-10-16 EC EC2008008827A patent/ECSP088827A/es unknown
- 2008-10-16 ZA ZA200808872A patent/ZA200808872B/xx unknown
- 2008-10-17 CO CO08110815A patent/CO6140037A2/es unknown
- 2008-11-14 NO NO20084810A patent/NO20084810L/no not_active Application Discontinuation
-
2009
- 2009-12-17 US US12/640,645 patent/US7807456B2/en active Active
-
2010
- 2010-08-27 US US12/869,813 patent/US7972604B2/en active Active
-
2011
- 2011-01-19 AR ARP110100176A patent/AR079941A2/es not_active Application Discontinuation
-
2013
- 2013-09-17 JP JP2013191854A patent/JP2013255518A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079941A2 (es) | Organismos clostridium atenuados recombinados y vacuna | |
| PE20161551A1 (es) | Vacuna de pcsk9 | |
| AR040204A1 (es) | Composicion de vacuna meningococica multivalente | |
| CL2009001874A1 (es) | Uso de bacillus subtilis qst713 nrrl b-21661 para formular una composición probiótica para un animal; y composición probiotica de bacillus subtilis qst713 nrrl b-21661. | |
| CL2009000091A1 (es) | Enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante; usos de la enzima galns contra mucopolisacaridosis tipo iv o sindrome de morquio a o deficiencias de multiples sulfatasas. | |
| CL2008002390A1 (es) | Composicion farmaceutica que comprende una variante de fenilalanina amino-liasa de anabaena variabilis (avpal); usos contra el cancer. | |
| AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
| MX2011006846A (es) | Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv. | |
| WO2008156778A3 (en) | Influenza m2 protein mutant viruses as live influenza attenuated vaccines | |
| MX347600B (es) | Uso de una composicion que comprende un peptido antimicrobiano como un conservador de alimentos. | |
| AR060565A1 (es) | Vacuna para la gripe aviaria y metodos de uso | |
| AR074311A1 (es) | Variantes de subtilisina aislada de bacillus, con actividad proteolitica | |
| BRPI0608796B8 (pt) | método para a preparação de um extrato de planta compreendendo bacuquiol | |
| ECSP099079A (es) | Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos | |
| ES2530670T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
| BR112017008304A2 (pt) | tripeptidil peptidases tolerantes à prolina e seus usos | |
| PE20121685A1 (es) | Antigeno ndv recombinante y usos del mismo | |
| PE20200514A1 (es) | Compuestos de mic-1 y usos de estos | |
| MX2025004075A (es) | Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos | |
| NZ602380A (en) | Peptides for vaccine against birch allergy | |
| ES2670799T3 (es) | Inmunógenos desintoxicados de Escherichia coli | |
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| ES2421447T3 (es) | Métodos para proteger frente a apoptosis usando lipopéptidos | |
| AR075933A1 (es) | Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso | |
| NZ594268A (en) | Grass peptides for vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |